# Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma

> **NCT05512481** · PHASE2 · RECRUITING · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 60 (estimated)

## Conditions studied

- Melanoma
- Acral Melanoma
- Temozolomide
- Apatinib
- Camrelizumab
- Neoadjuvant
- Pathological Response

## Interventions

- **DRUG:** Camrelizumab

## Key facts

- **NCT ID:** NCT05512481
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-09-13
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05512481

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05512481, "Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05512481. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*